Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.verified

KPTI

Price:

$0.89

Market Cap:

$110.91M

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or ...[Read more]

Industry

Biotechnology

IPO Date

2013-11-06

Stock Exchange

NASDAQ

Ticker

KPTI

The PE Ratio as of July 2024 (TTM) for Karyopharm Therapeutics Inc. (KPTI) is -0.70

According to Karyopharm Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.70. This represents a change of -37.65% compared to the average of -1.12 of the last 4 quarters.

Karyopharm Therapeutics Inc. (KPTI) Historical PE Ratio (quarterly & annually)

How has KPTI PE Ratio performed in the past?

The mean historical PE Ratio of Karyopharm Therapeutics Inc. over the last ten years is -4.69. The current -0.70 PE Ratio has changed 1.39% with respect to the historical average. Over the past ten years (40 quarters), KPTI's PE Ratio was at its highest in in the December 2021 quarter at 3.14. The PE Ratio was at its lowest in in the June 2014 quarter at -21.01.

Quarterly (TTM)
Annual

Average

-4.69

Median

-3.66

Minimum

-15.38

Maximum

-0.69

Karyopharm Therapeutics Inc. (KPTI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Karyopharm Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 275.41%

Maximum Annual PE Ratio = -0.69

Minimum Annual Increase = -74.03%

Minimum Annual PE Ratio = -15.38

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.69-59.00%
2022-1.68-56.79%
2021-3.90-31.40%
2020-5.68-4.51%
2019-5.9599.54%
2018-2.98-12.71%
2017-3.426.13%
2016-3.22-19.40%
2015-3.99-74.03%
2014-15.38275.41%

Karyopharm Therapeutics Inc. (KPTI) Average PE Ratio

How has KPTI PE Ratio performed in the past?

The current PE Ratio of Karyopharm Therapeutics Inc. (KPTI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.09

5-year avg

-3.58

10-year avg

-4.69

Karyopharm Therapeutics Inc. (KPTI) PE Ratio vs. Peers

How is KPTI’s PE Ratio compared to its peers?

Karyopharm Therapeutics Inc.’s PE Ratio is greater than X4 Pharmaceuticals, Inc. (-1.18), greater than HOOKIPA Pharma Inc. (-16.94), greater than Mereo BioPharma Group plc (-77.28), less than Galera Therapeutics, Inc. (-0.15), greater than Acumen Pharmaceuticals, Inc. (-3.07), less than CytomX Therapeutics, Inc. (6.85), greater than Nuvation Bio Inc. (-9.54), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Assembly Biosciences, Inc. (-1.62), less than Lyra Therapeutics, Inc. (-0.26), greater than Replimune Group, Inc. (-2.81), greater than Nuvectis Pharma, Inc. (-4.97), less than Kronos Bio, Inc. (-0.64), greater than Gossamer Bio, Inc. (-1.35), greater than Agios Pharmaceuticals, Inc. (-7.45), greater than bluebird bio, Inc. (-1.04), greater than Intercept Pharmaceuticals, Inc. (-13.55), less than PMV Pharmaceuticals, Inc. (0), greater than Rallybio Corporation (-1.23), greater than Generation Bio Co. (-0.72), greater than Mersana Therapeutics, Inc. (-1.13), greater than Monte Rosa Therapeutics, Inc. (-1.77), greater than null (-1.89),

Build a custom stock screener for Karyopharm Therapeutics Inc. (KPTI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Karyopharm Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Karyopharm Therapeutics Inc. (KPTI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Karyopharm Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Karyopharm Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for Karyopharm Therapeutics Inc. (KPTI)?

What is the highest PE Ratio for Karyopharm Therapeutics Inc. (KPTI)?

What is the 3-year average PE Ratio for Karyopharm Therapeutics Inc. (KPTI)?

What is the 5-year average PE Ratio for Karyopharm Therapeutics Inc. (KPTI)?

How does the current PE Ratio for Karyopharm Therapeutics Inc. (KPTI) compare to its historical average?